Kinder Morgan Del (KMI) Holder Highstar Capital LP Has Decreased Its Position by $1.52 Million as Share Price Declined; As Biogen (BIIB) Share Price Declined, Gmt Capital Has Lifted by $1.45 Million Its Position

June 14, 2018 - By Vivian Park

Biogen Inc. (NASDAQ:BIIB) Logo

Thomas E. Claugus increased its stake in Biogen Inc (BIIB) by 1.66% based on its latest 2018Q1 regulatory filing with the SEC. Gmt Capital Corp bought 5,300 shares as the company’s stock declined 1.31% with the market. The hedge fund run by Thomas E. Claugus held 324,400 shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $88.83 million, up from 319,100 at the end of the previous reported quarter. Gmt Capital Corp who had been investing in Biogen Inc for a number of months, seems to be bullish on the $64.47B market cap company. The stock decreased 0.45% or $1.37 during the last trading session, reaching $305.54. About 770,031 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 13.14% since June 14, 2017 and is uptrending. It has outperformed by 0.57% the S&P500. Some Historical BIIB News: 23/04/2018 – Biogen’s Tecfidera Falls After 1-Wk Rise, Avonex Declines: MS; 24/04/2018 – STAT Plus: Biogen’s rain-making rare-disease drug hits a sales slump; 20/04/2018 – Biogen’s Avonex Sales Fall; Multiple Sclerosis Market Down 1%; 15/05/2018 – Bridgewater Adds Biogen, Exits Costco, Buys More Newfield: 13F; 05/04/2018 – BIOGEN INC – BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018; 24/04/2018 – Biogen Reports Quarterly Revenues of $3.1 Billion; 12/03/2018 – BIOGEN: SPINRAZA TRIAL SHOWED IMPROVED MOTOR FUNCTION; 20/04/2018 – BIOGEN – CO, IONIS EXPANDED COLLABORATION THROUGH NEW 10-YR AGREEMENT TO DEVELOP NOVEL ANTISENSE DRUG CANDIDATES FOR RANGE OF NEUROLOGICAL DISEASES; 01/05/2018 – BIOGEN TO FURTHER CUT ADUCANUMAB ROYALTY RATES; 20/04/2018 – $BIIB $IONS Interesting slide on antisense and gene therapy being “Complementary”, “Combination / sequential”. Will see if Biogen answer any question re $AVXS

Highstar Capital Lp decreased its stake in Kinder Morgan Inc Del (KMI) by 17.28% based on its latest 2018Q1 regulatory filing with the SEC. Highstar Capital Lp sold 101,179 shares as the company’s stock declined 6.09% with the market. The hedge fund held 484,513 shares of the public utilities company at the end of 2018Q1, valued at $7.30M, down from 585,692 at the end of the previous reported quarter. Highstar Capital Lp who had been investing in Kinder Morgan Inc Del for a number of months, seems to be less bullish one the $37.42 billion market cap company. The stock increased 1.31% or $0.22 during the last trading session, reaching $16.96. About 5.84 million shares traded. Kinder Morgan, Inc. (NYSE:KMI) has declined 18.18% since June 14, 2017 and is downtrending. It has underperformed by 30.75% the S&P500. Some Historical KMI News: 29/05/2018 – KINDER MORGAN – DEAL WILL HAVE POSITIVE IMPACT ON CONSOL BALANCE SHEET, EXPECT KMI’S ABOUT 70 PCT SHARE OF AFTER TAX PROCEEDS TO BE ABOUT US$2.0 BLN; 29/05/2018 – Kinder Morgan Canada To Work With Bd to Seek Third-Party Buyer for Trans Mountain Pipeline System and TMEP Through July 22; 29/05/2018 – Canada to buy Kinder Morgan oil pipeline in bid to save project; 28/05/2018 – Canada likely to buy Trans Mountain pipeline project – Bloomberg; 29/05/2018 – KINDER MORGAN – GOVERNMENT OF CANADA AGREED TO FUND RESUMPTION OF TMEP PLANNING & CONSTRUCTION WORK BY GUARANTEEING TMEP’S ADVANCES; 18/04/2018 – Kinder Morgan: 2018 Is Set to Achieve DCF of Approximately $2.05 Per Common Share; 10/04/2018 – KINDER MORGAN PIPELINE ISSUE SHOULD BE SETTLED IN COURTS:HORGAN; 28/05/2018 – CANADA LIKELY TO BUY KINDER MORGAN CANADA TRANS MOUNTAIN OIL PIPELINE AND ITS EXPANSION PROJECT IN BID TO ENSURE IT IS BUILT- BLOOMBERG, CITING; 16/05/2018 – CANADA FINANCE MINISTER: ANY SUPPORT CANADA GIVES TO KINDER MORGAN CANADA MUST BE SOUND, FAIR AND BENEFIT ALL CANADIANS; 20/04/2018 – Kinder Morgan Nears $6.5 Billion in Kickoffs, Completions, Wary of Trans Mountain Expansion, an Industrial Info News Alert

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Benzinga.com which released: “Canaccord Upgrades Biogen On Deal Opportunities, Alzheimer’s Pipeline” on May 31, 2018, also Globenewswire.com with their article: “Biogen Appoints Daniel Karp as EVP, Corporate Development” published on May 31, 2018, Bizjournals.com published: “Biogen’s head of late-stage trials leaves for Sarepta” on June 07, 2018. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Streetinsider.com and their article: “Biogen (BIIB) & Samsung Bioepis Co. Report Joint Analysis Results of Anti-TNF Biosimilars BENEPALI (etanercept …” published on June 13, 2018 as well as Nasdaq.com‘s news article titled: “Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference” with publication date: June 13, 2018.

Gmt Capital Corp, which manages about $9.19B and $4.15B US Long portfolio, decreased its stake in Entegris Inc (NASDAQ:ENTG) by 433,800 shares to 8.78 million shares, valued at $305.50 million in 2018Q1, according to the filing. It also reduced its holding in Viad Corp (NYSE:VVI) by 306,727 shares in the quarter, leaving it with 527,765 shares, and cut its stake in Live Nation Entertainment In (NYSE:LYV).

Among 33 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 25 have Buy rating, 0 Sell and 8 Hold. Therefore 76% are positive. Biogen Idec Inc. had 133 analyst reports since July 23, 2015 according to SRatingsIntel. As per Monday, July 27, the company rating was upgraded by Bernstein. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Hold” rating by RBC Capital Markets on Friday, March 2. The firm has “Outperform” rating given on Wednesday, October 25 by BMO Capital Markets. As per Monday, July 27, the company rating was maintained by RBC Capital Markets. BMO Capital Markets downgraded Biogen Inc. (NASDAQ:BIIB) rating on Friday, July 24. BMO Capital Markets has “Market Perform” rating and $360 target. Standpoint Research initiated the stock with “Buy” rating in Thursday, January 7 report. On Wednesday, July 26 the stock rating was maintained by UBS with “Neutral”. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Tuesday, October 24 by Goldman Sachs. The stock has “Neutral” rating by UBS on Monday, June 19. The firm has “Buy” rating by Guggenheim given on Friday, March 2.

Investors sentiment decreased to 1.07 in Q1 2018. Its down 0.10, from 1.17 in 2017Q4. It dropped, as 69 investors sold BIIB shares while 305 reduced holdings. 92 funds opened positions while 308 raised stakes. 178.22 million shares or 1.35% less from 180.65 million shares in 2017Q4 were reported. Amer Bancshares owns 0% invested in Biogen Inc. (NASDAQ:BIIB) for 38 shares. Exane Derivatives owns 2,035 shares. Augustine Asset, Florida-based fund reported 9,665 shares. Mckinley Carter Wealth Svcs accumulated 400 shares or 0.04% of the stock. 299,879 were accumulated by Westfield Ltd Partnership. Paloma Ptnrs Mngmt reported 13,579 shares. Panagora Asset Mgmt has invested 0.44% of its portfolio in Biogen Inc. (NASDAQ:BIIB). 5,074 were reported by Ibm Retirement Fund. Thompson Siegel And Walmsley Ltd Llc invested in 0% or 396 shares. Mason Street Advsrs Llc reported 0.19% in Biogen Inc. (NASDAQ:BIIB). Kcm Advsrs Ltd Company holds 3,954 shares or 0.07% of its portfolio. Tortoise Invest Limited Com owns 68 shares. Factory Mutual Insur Com invested 0.53% in Biogen Inc. (NASDAQ:BIIB). Mirae Asset Glob invested 0.1% in Biogen Inc. (NASDAQ:BIIB). Wellington Mgmt Group Llp stated it has 5.07M shares.

Since January 9, 2018, it had 1 insider buy, and 5 selling transactions for $10.09 million activity. PANGIA ROBERT W sold $1.92M worth of stock or 5,832 shares. On Wednesday, April 25 DENNER ALEXANDER J bought $12.96M worth of Biogen Inc. (NASDAQ:BIIB) or 48,000 shares.

Analysts await Kinder Morgan, Inc. (NYSE:KMI) to report earnings on July, 18. They expect $0.19 EPS, up 35.71% or $0.05 from last year’s $0.14 per share. KMI’s profit will be $419.15M for 22.32 P/E if the $0.19 EPS becomes a reality. After $0.22 actual EPS reported by Kinder Morgan, Inc. for the previous quarter, Wall Street now forecasts -13.64% negative EPS growth.

Among 25 analysts covering Kinder Morgan (NYSE:KMI), 17 have Buy rating, 0 Sell and 8 Hold. Therefore 68% are positive. Kinder Morgan had 86 analyst reports since July 30, 2015 according to SRatingsIntel. On Thursday, October 22 the stock rating was maintained by Barclays Capital with “Overweight”. The stock of Kinder Morgan, Inc. (NYSE:KMI) earned “Buy” rating by Raymond James on Wednesday, May 31. The firm has “Hold” rating given on Thursday, October 22 by Stifel Nicolaus. RBC Capital Markets maintained Kinder Morgan, Inc. (NYSE:KMI) on Thursday, October 22 with “Outperform” rating. The company was maintained on Monday, April 30 by Stifel Nicolaus. The firm has “Hold” rating by Jefferies given on Monday, April 16. The company was maintained on Tuesday, June 20 by BMO Capital Markets. The rating was downgraded by Credit Suisse on Thursday, October 22 to “Neutral”. Bank of America upgraded the stock to “Buy” rating in Wednesday, March 21 report. The rating was maintained by Morgan Stanley on Friday, November 17 with “Overweight”.

Kinder Morgan, Inc. (NYSE:KMI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>